JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study

Showed that treatment with esketamine resulted in a statistically significant, clinically meaningful improvement in depressive symptoms at four hours, including a measure of suicidal ideation, in patients with major depressive disorder who were at imminent risk for suicide, compared to placebo.